125results about "Calcium binding proteins" patented technology

The present invention relates generally to the production and use of functionally active soluble HLA molecules that are isolated and purified substantially away from other proteins, and methods of purifying same.

The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein.

The present invention provides an “in vivo and in vitro real-time bioluminescence imaging means,” which can transmit a detection signal promptly in response to an external signal, while taking advantage of a single-molecule-format luminescent probe as a bioluminescent means.The present invention is characterized by using, as a single-molecule-format luminescent probe utilizing the increase and decrease of a second messenger level as an index, a fusion protein including a single-chain protein containing a second messenger recognition protein and optionally a peptide which is capable of binding with the protein, and linked respectively to the N-terminus and the C-terminus thereto, an N-terminal fragment (N-LE) and a C-terminal fragment (C-LE) generated by dissecting a luminescent enzyme (LE). A single-molecule-format luminescent probe could be provided, which makes it possible to observe light emission (extinction) in vivo as well as in vitro, as a result of a conformational change of the second messenger recognition protein induced by the binding (unbinding) with a second messenger, and the subsequent association or dissociation between the N-LE and the C-LE flanked at both termini of the recognition protein.

The presently-disclosed subject matter includes fluorescent protein-based indicators for detecting ions, small molecule analytes, or combinations thereof. In some embodiments the indicators include a polypeptide, which itself includes a fluorescent polypeptide, a compound-binding polypeptide, and a polypeptide target of the compound-binding polypeptide. In some embodiments the polypeptide includes an EosFP polypeptide, a calmodulin polypeptide, and a M13 polypeptide, or fragments and / or variants thereof. The presently-disclosed subject matter also includes methods for detecting calcium in a sample with embodiments of the present polypeptides. In some embodiments the present indicators experience a permanent shift from green to red fluorescent when exposed to an detecting substance, such as calcium.

The present invention relates generally to anti-MHC assay methodologies utilizing functionally active, recombinantly produced, and truncated individual soluble MHC trimolecular complexes that are linked to a substrate. The methods include reacting a sample with the substrate having the MHC trimolecular complex linked thereto, whereby antibodies specific for the at least one MHC trimolecular complex linked to the substrate are removed from the biological sample.

The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.

The present invention encompasses methods for generating mutant janus kinase 2 (JAK-2), mutant calreticulin (CALR), or thrombopoietin receptor (MPL) modified megakaryocytes (modified MKs) expressing a mutant Janus kinase 2 peptide, a mutant calreticulin peptide, and / or a mutant thrombopoietin receptor peptide, JAK2-, CALR-, and / or MPL-modified platelets as a composition of matter, and methods for using the generated JAK2-, CALR-, and / or MPL-modified platelets.